Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 98

Sort by

Sort Order Select

Journal Articles

Impact of Progression-Free Survival at 24 Months on Subsequent Survival in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP Therapy: A Supplementary Analysis of JCOG0601

Ayumi Fujimoto, Wataru Munakata, Gakuto Ogawa, Tomotaka Suzuki, Kazuyuki Shimada, Tsutomu Kobayashi, Ken Ohmachi, Tomohiro Kinoshita, Kiyoshi Ando, Dai Maruyama, Hirokazu Nagai

Blood (2023) 142 (Supplement 1): 4499.

https://doi.org/10.1182/blood-2023-173433

Published: 2023

Journal Articles

The Prognostic Impact of Relative Dose Intensity of Vincristine in R-CHOP for Untreated Patients with Diffuse Large B-Cell Lymphoma: A Supplementary Analysis of JCOG0601

Takahiro Nakashima, Tomotaka Suzuki, Gakuto Ogawa, Kazuyuki Shimada, Tsutomu Kobayashi, Dai Maruyama, Wataru Munakata, Ken Ohmachi, Tomohiro Kinoshita, Kiyoshi Ando, Hirokazu Nagai

Blood (2023) 142 (Supplement 1): 1741.

https://doi.org/10.1182/blood-2023-174354

Published: 2023

Journal Articles

Final Analysis of the Randomized Phase II/III Study of Standard R-CHOP Versus CHOP Combined with Dose-Dense Weekly Rituximab for DLBCL: JCOG0601

Blood (2023) 142 (Supplement 1): 1724.

https://doi.org/10.1182/blood-2023-178551

Published: 2023

Journal Articles

The hepatic niche leads to aggressive natural killer cell leukemia proliferation through the transferrin–transferrin receptor 1 axis

Blood (2023) 142 (4): 352–364.

https://doi.org/10.1182/blood.2022018597

Published: 2023

Includes: Supplemental data

Journal Articles

Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial

Blood (2023) 141 (16): 1971–1981.

https://doi.org/10.1182/blood.2022017734

Published: 2023

Includes: Supplemental data

Journal Articles

Primary Results of Stimulus-MDS1: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of TIM-3 Inhibition with Sabatolimab Added to Hypomethylating Agents (HMAs) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS)

Amer M. Zeidan, Kiyoshi Ando, Odile Rauzy, Mehmet Turgut, Ming-Chung Wang, Roberto Cairoli, Hsin-An Hou, Yok-Lam Kwong, Montserrat Arnan Sangerman, Stef Meers, Vinod A. Pullarkat, Valeria Santini, Kamel Malek, Flavia Kiertsman, Jiaying Lyu, Pedro Marques Ramos, Pierre Fenaux, Yasushi Miyazaki, Uwe Platzbecker

Blood (2022) 140 (Supplement 1): 2063–2065.

https://doi.org/10.1182/blood-2022-158612

Published: 2022

Journal Articles

Final Analysis of JCOG0203 for Advanced-Stage Indolent B-Cell Lymphoma 15 Years after the End of Enrollment: Pooled Analysis of Arms a and B for Follicular Lymphoma

Takashi Watanabe, Kensei Tobinai, Ｍasashi Wakabayashi, Dai Maruyama, Kazuhito Yamamoto, Nobuko Kubota, Kazuyuki Shimada, Kohsuke Asagoe, Motoko Yamaguchi, Kiyoshi Ando, Michinori Ogura, Junya Kuroda, Youko Suehiro, Yoshihiro Matsuno, Kunihiro Tsukasaki, Hirokazu Nagai

Blood (2022) 140 (Supplement 1): 3615–3617.

https://doi.org/10.1182/blood-2022-159967

Published: 2022

Journal Articles

Six-Year Results from the Phase 3 Randomized Study Relevance Show Similar Outcomes for Previously Untreated Follicular Lymphoma Patients Receiving Lenalidomide Plus Rituximab (R 2 ) Versus Rituximab-Chemotherapy Followed By Rituximab Maintenance

Blood (2021) 138 (Supplement 1): 2417.

https://doi.org/10.1182/blood-2021-148218

Published: 2021

Journal Articles

Clinical Significance of Small PNH-Type Cell Populations in Bone Marrow Failure Syndromes - an Interim Analysis of Japanese Multicentrer Prospective Study -

Yasutaka Ueda, Kohei Hosokawa, Ken Ishiyama, Hiroyuki Takamori, Yuji Yonemura, Naoshi Obara, Hideyoshi Noji, Kiyoshi Ando, Tsutomu Shichishima, Takayuki Ikezoe, Shigeru Chiba, Haruhiko Ninomiya, Tatsuya Kawaguchi, Jun-ichi Nishimura, Yuzuru Kanakura, Shinji Nakao

Blood (2021) 138 (Supplement 1): 1122.

https://doi.org/10.1182/blood-2021-146353

Published: 2021

Journal Articles

Asian Multinational Phase II Study of Darinaparsin in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

Noriko Fukuhara, Won Seog Kim, Dok Hyun Yoon, Eiju Negoro, Kazuhito Yamamoto, Toshiki Uchida, Koji Izutsu, Yasuhito Terui, Hideaki Nakajima, Kiyoshi Ando, Youko Suehiro, Hye Jin Kang, Po-Shen Ko, Fumiko Nagahama, Yusuke Sonehara, Hirokazu Nagai, Hwei-Fang Tien, Yok-Lam Kwong, Kensei Tobinai

Blood (2021) 138 (Supplement 1): 1376.

https://doi.org/10.1182/blood-2021-145512

Published: 2021

Journal Articles

The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications

Daisuke Ogiya, Jiye Liu, Hiroto Ohguchi, Keiji Kurata, Mehmet K. Samur, Yu-Tzu Tai, Sophia Adamia, Kiyoshi Ando, Teru Hideshima, Kenneth C. Anderson

Blood (2020) 136 (20): 2334–2345.

https://doi.org/10.1182/blood.2019004332

Published: 2020

Includes: Supplemental data

Journal Articles

Phase 1 Study of Alvocidib (DSP-2033) in Combination with Cytarabine/Mitoxantrone (ACM) or Cytarabine/Daunorubicin (A+7+3) in Japanese Patients (Pts) with Acute Myeloid Leukemia (AML)

Yasuyoshi Morita, Takayuki Ikezoe, MD PhD, Kiyoshi Ando, Masahiro Onozawa, Takahisa Yamane, MD PhD, Naoko Hosono, MD PhD, Toru Kiguchi, Hiromi Iwasaki, Toshihiro Miyamoto, MD PhD, Miho Kasai, Saori Sugimoto, Yasushi Miyazaki, MD PhD, Masahiro Kizaki, MD, Koichi Akashi, MD PhD

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-134078

Published: 2020

Journal Articles

Validation of the PRIMA-Prognostic Index for Patients Treated with Rituximab Plus Chemotherapy and Refinement of Prognostic Parameters for Patients on Rituximab Plus Lenalidomide in the Phase III Relevance Trial

Blood (2019) 134 (Supplement_1): 1524.

https://doi.org/10.1182/blood-2019-129024

Published: 2019

Journal Articles

Bone Marrow Adipocyte-Derived PAI-1 As a Negative Regulator of Hematopoietic Regeneration

Kaito Harada, MD, Makoto Onizuka, MD PhD, Takashi Yahata, PhD, Abd Aziz Ibrahim, PhD, Eri Kikkawa, PhD, Toshio Miyata, MD, PhD, Kiyoshi Ando

Blood (2019) 134 (Supplement_1): 2489.

https://doi.org/10.1182/blood-2019-125672

Published: 2019

Journal Articles

Phase 2 Study of E7777, a Diphtheria Toxin Fragment-Interleukin-2 Fusion Protein, in Japanese Patients with Relapsed or Refractory Peripheral and Cutaneous T-Cell Lymphoma

Blood (2019) 134 (Supplement_1): 4032.

https://doi.org/10.1182/blood-2019-121723

Published: 2019

Journal Articles

Durvalumab (Anti PD-L1) As Monotherapy or in Combination Therapy for Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL): A Subgroup Analysis from the Phase 1/2 Fusion NHL-001 Global Multicenter Trial

Blood (2019) 134 (Supplement_1): 5320.

https://doi.org/10.1182/blood-2019-124102

Published: 2019

Journal Articles

Randomized Phase II/III Study of Standard R-CHOP Versus CHOP Combined with Dose-Dense Weekly Rituximab (RW-CHOP) for Previously Untreated DLBCL: JCOG0601

Blood (2018) 132 (Supplement 1): 4194.

https://doi.org/10.1182/blood-2018-99-110201

Published: 2018

Journal Articles

Role of exosomes as a proinflammatory mediator in the development of EBV-associated lymphoma

Blood (2018) 131 (23): 2552–2567.

https://doi.org/10.1182/blood-2017-07-794529

Published: 2018

Includes: Supplemental data

Journal Articles

Updated Report of a Phase I/II Multicenter Study of Forodesine, a Purine Nucleoside Phosphorylase Inhibitor, in Japanese Patients with Relapsed Peripheral T-Cell Lymphoma

Blood (2017) 130 (Supplement 1): 4075.

https://doi.org/10.1182/blood.V130.Suppl_1.4075.4075

Published: 2017

Journal Articles

A Phase II Study of THP-COP (pirarubicin, cyclophosphamide, vincristine and prednisolone) in Patients with Newly Diagnosed Advanced Peripheral T-Cell Lymphoma: THP-3 Study of Japan Hematopoietic Malignancy Clinical Study Group (HMCSG)

Michinori Ogura, MD PhD, Ken Ohmachi, MD, Ritsuro Suzuki, MD PhD, Yoshiko Atsuta, MD PhD, Tatsuya Ito, MD, Kazuma Ohyashiki, MD, Shingo Yano, MD PhD, Michihiro Hidaka, MD PhD, Kiyoshi Ando, MD PhD, Noriko Fukuhara, MD PhD, Yoshihisa Morishita, MD PhD, Takayo Suzuki, MD PhD, Kunihiro Tsukasaki, MD PhD, Naoki Kobayashi, MD PhD, Kenji Tsukamoto, MD, Yukiyasu Ozawa, MD PhD, Tomomitsu Hotta, MD PhD, Tomohiro Kinoshita, MD PhD

Blood (2017) 130 (Supplement 1): 2789.

https://doi.org/10.1182/blood.V130.Suppl_1.2789.2789

Published: 2017

NARROW

Impact of Progression-Free Survival at 24 Months on Subsequent Survival in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP Therapy: A Supplementary Analysis of JCOG0601

The Prognostic Impact of Relative Dose Intensity of Vincristine in R-CHOP for Untreated Patients with Diffuse Large B-Cell Lymphoma: A Supplementary Analysis of JCOG0601

Final Analysis of the Randomized Phase II/III Study of Standard R-CHOP Versus CHOP Combined with Dose-Dense Weekly Rituximab for DLBCL: JCOG0601

The hepatic niche leads to aggressive natural killer cell leukemia proliferation through the transferrin–transferrin receptor 1 axis

Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial

Primary Results of Stimulus-MDS1: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of TIM-3 Inhibition with Sabatolimab Added to Hypomethylating Agents (HMAs) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS)

Final Analysis of JCOG0203 for Advanced-Stage Indolent B-Cell Lymphoma 15 Years after the End of Enrollment: Pooled Analysis of Arms a and B for Follicular Lymphoma

Six-Year Results from the Phase 3 Randomized Study Relevance Show Similar Outcomes for Previously Untreated Follicular Lymphoma Patients Receiving Lenalidomide Plus Rituximab (R 2 ) Versus Rituximab-Chemotherapy Followed By Rituximab Maintenance

Clinical Significance of Small PNH-Type Cell Populations in Bone Marrow Failure Syndromes - an Interim Analysis of Japanese Multicentrer Prospective Study -

Asian Multinational Phase II Study of Darinaparsin in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications

Phase 1 Study of Alvocidib (DSP-2033) in Combination with Cytarabine/Mitoxantrone (ACM) or Cytarabine/Daunorubicin (A+7+3) in Japanese Patients (Pts) with Acute Myeloid Leukemia (AML)

Validation of the PRIMA-Prognostic Index for Patients Treated with Rituximab Plus Chemotherapy and Refinement of Prognostic Parameters for Patients on Rituximab Plus Lenalidomide in the Phase III Relevance Trial

Bone Marrow Adipocyte-Derived PAI-1 As a Negative Regulator of Hematopoietic Regeneration

Phase 2 Study of E7777, a Diphtheria Toxin Fragment-Interleukin-2 Fusion Protein, in Japanese Patients with Relapsed or Refractory Peripheral and Cutaneous T-Cell Lymphoma

Durvalumab (Anti PD-L1) As Monotherapy or in Combination Therapy for Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL): A Subgroup Analysis from the Phase 1/2 Fusion NHL-001 Global Multicenter Trial

Randomized Phase II/III Study of Standard R-CHOP Versus CHOP Combined with Dose-Dense Weekly Rituximab (RW-CHOP) for Previously Untreated DLBCL: JCOG0601

Role of exosomes as a proinflammatory mediator in the development of EBV-associated lymphoma

Updated Report of a Phase I/II Multicenter Study of Forodesine, a Purine Nucleoside Phosphorylase Inhibitor, in Japanese Patients with Relapsed Peripheral T-Cell Lymphoma

A Phase II Study of THP-COP (pirarubicin, cyclophosphamide, vincristine and prednisolone) in Patients with Newly Diagnosed Advanced Peripheral T-Cell Lymphoma: THP-3 Study of Japan Hematopoietic Malignancy Clinical Study Group (HMCSG)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only